Vinblastine News and Research

RSS

Vinblastine is the active ingredient in a drug used together with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Vinblastine comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.

Kaempferol's promise in fighting triple-negative breast cancer

Review highlights kaempferol's potential in treating triple-negative breast cancer through various anticancer mechanisms and improving chemotherapeutic efficacy.

24 Jul 2024

Innovative technique speeds up search for antimicrobial drug candidates

A method to screen a wide variety of drug candidates without laborious purification steps could advance the fight against drug-resistant bacteria.

11 Jul 2024

NCCN survey reveals ongoing shortages in crucial cancer medications

The National Comprehensive Cancer Network (NCCN)-;a nonprofit alliance of leading cancer centers-;is publishing new results for its latest survey on cancer drug shortages in the United States.

26 Jun 2024

Advances in Diels-Alder synthesis of hydrocarbazole compounds using lanthanide catalysts

Hydrocarbazole is a crucial compound in organic chemistry, serving as a building block for various biologically active compounds, including pesticides like strychnine and anticancer drugs such as vinblastine and minovincine.

24 Jun 2024

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

An international team of researchers has demonstrated that genetically engineered yeast cells can produce the natural plant product alstonine, which has shown positive effects in treating schizophrenia.

10 Nov 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

Did the diagnosis and management of Hodgkin lymphoma differ during the SARS-CoV-2 pandemic?

In a new study, researchers evaluated the impact of the SARS-CoV-2 pandemic on the diagnosis and treatment of classical Hodgkin lymphoma (cHL) patients in Istanbul, Turkey.

17 Oct 2022

Biomarker could predict pathologic response to chemotherapy among bladder cancer patients

Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.

15 Feb 2022

Polymeric nanomicelles effectively deliver anti-cancer drugs to glioblastoma

Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.

12 Nov 2020

Study shows superior functionality of Duodenum Intestine-Chip populated with organoids

Emulate, Inc. announced today a published study in collaboration with Johns Hopkins University School of Medicine, that demonstrated superior functionality of the Duodenum Intestine-Chip populated with organoids, compared to organoids alone.

14 Jan 2020

Increasing anti-tumor activity of compound extracted from an Amazon plant

Researchers in Brazil have prepared modified forms of the alkaloids produced by Uncaria guianensis, a woody vine native to the Amazon Rainforest.

31 Oct 2019

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy even when all traces of the cancer appear to have gone, according to late breaking results presented at the ESTRO 38 conference today.

29 Apr 2019

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine chemotherapy, which is the standard of care.

5 Sep 2018

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.

31 Aug 2018

OSU scientists find way to fight solid tumors using new cancer-drug delivery system

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment.

4 Apr 2017

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

Women treated with a common chemotherapy drug combination have more young eggs in their ovaries afterwards, research has found.

6 Dec 2016

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.

9 Apr 2015

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014